Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Editorial Volume 4 Issue 4

Treatment of Hepatitis Viruses; Costly and Inaccessible

Oumer Abdu Muhie1* and Habtewold Shibru2

1Assistant Professor of Medicine, GAMBY Teaching General Hospital, Bahir Dar, Ethiopia
2Assistant Professor of Medicine, University of Gondar, Gondar, Ethiopia

*Corresponding Author: Oumer Abdu Muhie, Assistant Professor of Medicine, GAMBY Teaching General Hospital, Bahir Dar, Ethiopia.

Received: February 12, 2021; Published: February 27, 2021

×

  Hepatitis viruses B (HBV) and C (HCV) are major causes of liver diseases worldwide generally and in developing countries specifically. More than 70 million of the world population is estimated to be infected with hepatitis C virus. The World Health organization (WHO) has planned to eliminate HCV from the globe by the year 2030 [1]. Similarly estimated 240 million people were infected by HBV by 2005 globally [2].

  With the advent of direct acting antiviruses it is possible to cure hepatitis C virus [3]. The aforementioned WHO plan can only be achieved if the effective direct acting antiviruses are distributed in an equitable and affordable ways. Though there is no cure to hepatitis B virus currently its untoward consequences can be significantly alleviated by using effective antiviruses in those who require treatment [4].

  The treatment cost of the anti-hepatitis C virus medications varies depending on the manufacturer. Treatment of HCV is believed to be cost effective [5,6]. However, if one from a developing country agrees to take the HCV eradication therapy he or she may be obliged to sell important personal assets [7]. This is an obstacle for the poor as selling an asset could compromise the basic needs of the individual and the family.

  Similarly, there are various options for the treatment of hepatitis B virus infection. Tenofovir is one of the drugs used in the treatment of hepatitis B virus; however it too is costly and difficult to access especially in developing countries.

  To halt the untoward consequences of these deadly hepatitis viruses, their treatment shall be made available in affordable prices for those who require it. Likewise, if the WHO is to achieve its goal the treatments shall be made available to the poor on a reasonable price.

  To halt the untoward consequences of these deadly hepatitis vi-ruses, their treatment shall be made available in affordable prices for those who require it. Likewise, if the WHO is to achieve its goal the treatments shall be made available to the poor on a reasonable price.

×

Citation

Citation: Oumer Abdu Muhie and Habtewold Shibru . “The Role of Oxidative Stress and Antioxidant Effects in Female Endometriosis: A Systematic Review”. Acta Scientific Gastrointestinal Disorders 4.4 (2021): 01-02.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor0.835

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US